{"id":"soc-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"5-15%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of chemotherapy drugs in SOC chemotherapy targets rapidly dividing cancer cells, disrupting their growth and spread. This approach can help slow or stop cancer progression, but it can also cause side effects due to its impact on healthy cells.","oneSentence":"SOC chemotherapy involves administering a combination of chemotherapy drugs to treat cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:03.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various cancers, including breast, lung, colon, and ovarian cancer"}]},"trialDetails":[{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT06824467","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-09","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":770},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma","enrollment":3680},{"nctId":"NCT07281417","phase":"PHASE2","title":"Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-11-24","conditions":"Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8","enrollment":108},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT07283939","phase":"NA","title":"Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2026-02-13","conditions":"Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile","enrollment":420},{"nctId":"NCT04432207","phase":"PHASE1","title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2020-11-30","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":24},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT07491445","phase":"PHASE3","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2026-03-09","conditions":"Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC","enrollment":900},{"nctId":"NCT07260175","phase":"PHASE2","title":"Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-11-18","conditions":"Cholangiocarcinoma, IDH Mutation","enrollment":40},{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT06915025","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2025-07-09","conditions":"Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer","enrollment":500},{"nctId":"NCT07005102","phase":"PHASE2, PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-08-03","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":854},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":"Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions","enrollment":204},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT06467357","phase":"PHASE3","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-12","conditions":"Biliary Tract Cancer","enrollment":620},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT04658862","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-07","conditions":"Urinary Bladder Neoplasms","enrollment":518},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT06141031","phase":"PHASE1","title":"Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-01-16","conditions":"Pancreatic Cancer","enrollment":5},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":"Solid Tumors, Hematologic Malignancies","enrollment":3500},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03360890","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2018-03-26","conditions":"Thyroid Cancer, Salivary Gland Cancer","enrollment":46},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT03164616","phase":"PHASE3","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-06-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":1186},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT03003962","phase":"PHASE3","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-01-02","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":669},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":40},{"nctId":"NCT07079631","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-18","conditions":"Metastatic Colorectal Cancer","enrollment":482},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT05934448","phase":"PHASE2","title":"Pembro Plus CAR T-cell Therapy in R/R in PMBCL","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-11-15","conditions":"Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT05801913","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-09-29","conditions":"High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma","enrollment":15},{"nctId":"NCT07136493","phase":"NA","title":"Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2026-05-12","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":350},{"nctId":"NCT03313778","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2017-08-14","conditions":"Solid Tumors","enrollment":161},{"nctId":"NCT05673148","phase":"PHASE3","title":"Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-09","conditions":"Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8","enrollment":364},{"nctId":"NCT07059884","phase":"NA","title":"Distance-Based Exercise to Preserve Function and Prevent Disability","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2026-02-11","conditions":"Hematopoietic and Lymphatic System Neoplasm, Localized Malignant Solid Neoplasm","enrollment":104},{"nctId":"NCT07223190","phase":"PHASE3","title":"A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia","status":"NOT_YET_RECRUITING","sponsor":"Amgen","startDate":"2026-06-11","conditions":"Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia","enrollment":560},{"nctId":"NCT07225270","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy","status":"RECRUITING","sponsor":"Genmab","startDate":"2026-03-16","conditions":"Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC","enrollment":528},{"nctId":"NCT06208826","phase":"PHASE2","title":"A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-09-01","conditions":"Head and Neck Cancer","enrollment":268},{"nctId":"NCT04542824","phase":"PHASE1, PHASE2","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-08-20","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma","enrollment":78},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07206056","phase":"PHASE1, PHASE2","title":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-10-15","conditions":"Progressive Metastatic Castrate Resistant Prostate Cancer","enrollment":188},{"nctId":"NCT06309745","phase":"","title":"THERApy De-escalation for TESTicular Cancer","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-06-24","conditions":"Seminoma","enrollment":30},{"nctId":"NCT02453282","phase":"PHASE3","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-07-21","conditions":"Non-Small-Cell Lung Carcinoma NSCLC","enrollment":1118},{"nctId":"NCT06040762","phase":"NA","title":"A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-12-19","conditions":"Bladder Cancer, Urothelial Carcinoma, Upper Tract Urothelial Carcinoma","enrollment":128},{"nctId":"NCT06452277","phase":"PHASE3","title":"A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-08-28","conditions":"Advanced Non-small Cell Lung Cancer, HER2 Mutation","enrollment":278},{"nctId":"NCT05544136","phase":"PHASE2","title":"A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-12","conditions":"Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Neoplasms","enrollment":12},{"nctId":"NCT06996782","phase":"PHASE1, PHASE2","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":152},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT07425808","phase":"PHASE2, PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":"AML (Acute Myeloid Leukemia)","enrollment":230},{"nctId":"NCT06546553","phase":"PHASE1","title":"A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-09-06","conditions":"Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":10},{"nctId":"NCT05464082","phase":"PHASE2","title":"Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-01-06","conditions":"Breast Cancer Recurrent","enrollment":80},{"nctId":"NCT07102940","phase":"PHASE2","title":"Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2026-05-01","conditions":"Breast Cancer, HER 2 Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer","enrollment":50},{"nctId":"NCT07155850","phase":"NA","title":"Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC","status":"RECRUITING","sponsor":"BetaGlue Therapeutics SpA","startDate":"2026-02-03","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced, Unresectable","enrollment":10},{"nctId":"NCT07418034","phase":"PHASE2","title":"A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-05","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma","enrollment":132},{"nctId":"NCT06290687","phase":"PHASE2","title":"Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-02-18","conditions":"Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT07217990","phase":"PHASE1, PHASE2","title":"Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-04-15","conditions":"Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer","enrollment":84},{"nctId":"NCT07144826","phase":"EARLY_PHASE1","title":"Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-03-09","conditions":"Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8","enrollment":161},{"nctId":"NCT06710418","phase":"NA","title":"Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-10-15","conditions":"Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":50},{"nctId":"NCT02542293","phase":"PHASE3","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2015-11-03","conditions":"Non Small Cell Lung Carcinoma NSCLC","enrollment":953},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT07407517","phase":"PHASE3","title":"Adjuvant Intensification for LAR","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Breast Cancer Females, Triple Negative Breast Cancer (TNBC)","enrollment":904},{"nctId":"NCT03516708","phase":"PHASE1, PHASE2","title":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-06","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT04994717","phase":"PHASE3","title":"Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Amgen","startDate":"2021-11-02","conditions":"Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)","enrollment":304},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer NSCLC","enrollment":401},{"nctId":"NCT06307548","phase":"PHASE1, PHASE2","title":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer","status":"SUSPENDED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-07-30","conditions":"Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer","enrollment":21},{"nctId":"NCT06860269","phase":"PHASE2, PHASE3","title":"A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-05-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":1200},{"nctId":"NCT03904186","phase":"NA","title":"Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-12-19","conditions":"Human Immunodeficiency Virus, Smoking Cessation, Smoking, Cigarette","enrollment":131},{"nctId":"NCT07250477","phase":"PHASE2","title":"Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2026-01-30","conditions":"Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, Non Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT04662034","phase":"NA","title":"Performance and Safety of the Cardiac Microcurrent Therapy System","status":"COMPLETED","sponsor":"Berlin Heals GmbH","startDate":"2021-02-05","conditions":"Systolic Left Ventricular Dysfunction","enrollment":70},{"nctId":"NCT07392580","phase":"PHASE2","title":"Intralesional Chemotherapy (IC): Cisplatin + Epinephrine","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04-01","conditions":"Laryngeal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT04700124","phase":"PHASE3","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-04-21","conditions":"Bladder Cancer","enrollment":808},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT03682068","phase":"PHASE3","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-09-27","conditions":"Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer","enrollment":1246},{"nctId":"NCT06319963","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Theravectys S.A.","startDate":"2024-08-08","conditions":"HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":72},{"nctId":"NCT06895473","phase":"PHASE2","title":"Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-04","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":26},{"nctId":"NCT07252232","phase":"PHASE3","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2025-12-15","conditions":"Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":500},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT04421820","phase":"PHASE1, PHASE2","title":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","status":"RECRUITING","sponsor":"Bold Therapeutics, Inc.","startDate":"2020-08-28","conditions":"Colorectal Cancer, Pancreatic Cancer, Gastric Cancers","enrollment":220},{"nctId":"NCT05792150","phase":"","title":"PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS","status":"RECRUITING","sponsor":"West German Study Group","startDate":"2022-12-07","conditions":"Female Breast Cancer","enrollment":1470},{"nctId":"NCT07365995","phase":"PHASE3","title":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"BioNTech SE","startDate":"2026-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":736},{"nctId":"NCT07218913","phase":"PHASE1","title":"Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-04","conditions":"Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor","enrollment":44},{"nctId":"NCT07365319","phase":"PHASE2, PHASE3","title":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2026-05-18","conditions":"Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC","enrollment":750},{"nctId":"NCT07188532","phase":"NA","title":"Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-24","conditions":"Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion","enrollment":141},{"nctId":"NCT05846789","phase":"PHASE2","title":"SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers","status":"RECRUITING","sponsor":"Kathy Miller","startDate":"2024-07-02","conditions":"Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer","enrollment":168},{"nctId":"NCT06746116","phase":"PHASE3","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-30","conditions":"Advanced or Recurrent Endometrial Cancer","enrollment":45},{"nctId":"NCT07227909","phase":"PHASE2","title":"NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-04","conditions":"Psilocybin, Neuropathy","enrollment":83},{"nctId":"NCT07340164","phase":"PHASE2","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12-30","conditions":"Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent","enrollment":116},{"nctId":"NCT07333651","phase":"PHASE2","title":"125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Oligometastatic Disease","enrollment":90},{"nctId":"NCT06466382","phase":"NA","title":"OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy","status":"RECRUITING","sponsor":"Swiss GO Trial Group","startDate":"2025-03-31","conditions":"Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma","enrollment":60},{"nctId":"NCT07231757","phase":"","title":"The RADIANCE CED Study","status":"RECRUITING","sponsor":"ReCor Medical, Inc.","startDate":"2025-11-21","conditions":"Hypertension, Cardiovascular Diseases, Vascular Diseases","enrollment":1000},{"nctId":"NCT06124118","phase":"PHASE1","title":"Tumor Treating Fields for Locally Advanced NSCLC","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-04-04","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06680622","phase":"PHASE2","title":"Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-03","conditions":"Metastatic Gastro-esophageal Adenocarcinoma","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["diverse"],"phase":"phase_3","status":"active","brandName":"SOC chemotherapy","genericName":"SOC chemotherapy","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SOC chemotherapy, also known as Standard of Care chemotherapy, is used to treat various conditions including Ovarian Cancer, Platinum-sensitive Ovarian Cancer, Non-Squamous Non-Small Cell Lung Cancer, and Advanced Microsatellite Stable Colorectal Cancer. The mechanism of SOC chemotherapy involves the use of a Granulocyte colony-stimulating factor receptor agonist, which is a protein modality that stimulates the granulocyte colony-stimulating factor receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}